MXPA02012064A - Complejos de farmaco macromoleculares y composiciones que los contienen. - Google Patents

Complejos de farmaco macromoleculares y composiciones que los contienen.

Info

Publication number
MXPA02012064A
MXPA02012064A MXPA02012064A MXPA02012064A MXPA02012064A MX PA02012064 A MXPA02012064 A MX PA02012064A MX PA02012064 A MXPA02012064 A MX PA02012064A MX PA02012064 A MXPA02012064 A MX PA02012064A MX PA02012064 A MXPA02012064 A MX PA02012064A
Authority
MX
Mexico
Prior art keywords
same
complexes
compositions containing
disease
drug
Prior art date
Application number
MXPA02012064A
Other languages
English (en)
Inventor
Camillia Zamiri
Original Assignee
Trustess Of The University Of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustess Of The University Of filed Critical Trustess Of The University Of
Publication of MXPA02012064A publication Critical patent/MXPA02012064A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen complejos de farmaco macromoleculares que contienen un farmaco, como la hormona del crecimiento humano, y un polimero que tenga una pluralidad de porciones acidas, tales como porciones carboxilo o porciones de acido fosfonico, y composiciones que los contienen. Las composiciones, en particular microemulsiones, que contienen a los complejos macromoleculares se administran a individuos que padecen de una enfermedad o condicion, y los complejos liberan el farmaco in vivo, para tratar la enfermedad o condicion, y para reducir, eliminar o revertir las complicaciones asociadas con la enfermedad.
MXPA02012064A 2000-06-08 2001-05-17 Complejos de farmaco macromoleculares y composiciones que los contienen. MXPA02012064A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/589,721 US6417237B1 (en) 2000-06-08 2000-06-08 Macromolecular drug complexes and compositions containing the same
PCT/US2001/016163 WO2001093911A2 (en) 2000-06-08 2001-05-17 Macromolecular drug complexes and compositions containing the same

Publications (1)

Publication Number Publication Date
MXPA02012064A true MXPA02012064A (es) 2004-08-19

Family

ID=24359207

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012064A MXPA02012064A (es) 2000-06-08 2001-05-17 Complejos de farmaco macromoleculares y composiciones que los contienen.

Country Status (12)

Country Link
US (1) US6417237B1 (es)
EP (1) EP1286659A2 (es)
JP (1) JP2003535149A (es)
CN (1) CN1441666A (es)
AU (1) AU2001263277A1 (es)
BR (1) BR0111506A (es)
CA (1) CA2409268A1 (es)
CR (1) CR6834A (es)
IL (1) IL152978A0 (es)
MX (1) MXPA02012064A (es)
WO (1) WO2001093911A2 (es)
ZA (1) ZA200209229B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60321572D1 (de) * 2002-06-20 2008-07-24 Amnon Sintov Transdermales arzneimittelverabreichungssystem
WO2004060920A1 (en) * 2002-12-31 2004-07-22 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers
JP4686361B2 (ja) * 2002-12-31 2011-05-25 アルタス ファーマシューティカルズ インコーポレイテッド ヒト成長ホルモンの結晶およびその調製方法
US20060281675A1 (en) * 2003-08-20 2006-12-14 Neuren Pharmaceuticals Limited Somatogenic therapy using a 20kda placental variant of growth hormone
WO2005047334A1 (en) 2003-11-13 2005-05-26 Hanmi Pharmaceutical. Co., Ltd. Igg fc fragment for a drug carrier and method for the preparation thereof
US20050147581A1 (en) * 2003-11-19 2005-07-07 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes having improved stability and therapeutic use of the same
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
EP1797870A1 (en) * 2005-12-14 2007-06-20 The Jordanian Pharmaceutical Manufacturing Co. Oral delivery of protein drugs using microemulsion
WO2007076131A2 (en) * 2005-12-23 2007-07-05 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
US9107822B2 (en) 2010-09-03 2015-08-18 Santen Sas Water-in oil type emulsion for treating a disease of the eye
AU2011298298B2 (en) * 2010-09-03 2016-04-21 Santen Sas A water-in-oil type emulsion for treating a disease of the eye
EP2425814B1 (en) * 2010-09-03 2013-06-19 Novagali Pharma S.A. A water-in-oil type emulsion for treating a disease of the eye
WO2013101749A1 (en) * 2011-12-29 2013-07-04 Latitude Pharmaceuticals, Inc. Stabilized glucagon nanoemulsions
EP3043810B1 (en) 2013-09-09 2019-10-23 CanImGuide Therapeutics AB Immune system modulators
US10034834B1 (en) * 2014-10-24 2018-07-31 Aqua Regenerative Therapies Llc Compositions and methods for treating skin conditions
WO2016069409A1 (en) 2014-10-27 2016-05-06 Latitude Pharmaceuticals, Inc. Parenteral glucagon formulations
WO2016144650A1 (en) 2015-03-06 2016-09-15 Canimguide Therapeutics Ab Immune system modulators and compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE636812A (es) * 1958-10-06
US4003792A (en) 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US3577534A (en) 1968-06-20 1971-05-04 Canada Packers Ltd Stable orally active heparinoid complexes
WO1983000150A1 (en) * 1981-07-02 1983-01-20 Walton, Alan, G. Glycosaminoglycan drug complexes
US4585754A (en) 1984-01-09 1986-04-29 Valcor Scientific, Ltd. Stabilization of proteins and peptides by chemical binding with chondroitin
US5008109A (en) 1984-05-25 1991-04-16 Vestar, Inc. Vesicle stabilization
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
KR930001305B1 (ko) 1989-10-19 1993-02-25 니뽕 유우시 가부시끼가이샤 당 응답형 고분자 복합체(Polymer Complexes of Sugar Response Type)
GB9007052D0 (en) 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
AU709008B2 (en) 1994-12-22 1999-08-19 Access Pharmaceuticals, Inc. Complexes of dermatan sulfate and drugs, giving improved pharmacokinetics
WO1997037680A1 (en) 1996-04-05 1997-10-16 The Board Of Trustees Of The University Of Illinois Macromolecular complexes for drug delivery

Also Published As

Publication number Publication date
ZA200209229B (en) 2003-08-07
IL152978A0 (en) 2003-06-24
CN1441666A (zh) 2003-09-10
CR6834A (es) 2004-03-03
AU2001263277A1 (en) 2001-12-17
BR0111506A (pt) 2003-06-24
WO2001093911A2 (en) 2001-12-13
US6417237B1 (en) 2002-07-09
WO2001093911A3 (en) 2002-03-07
CA2409268A1 (en) 2001-12-13
EP1286659A2 (en) 2003-03-05
JP2003535149A (ja) 2003-11-25

Similar Documents

Publication Publication Date Title
MXPA02012064A (es) Complejos de farmaco macromoleculares y composiciones que los contienen.
CA2251008A1 (en) Macromolecular complexes for drug delivery
EP2014292A3 (en) Fenoldopam for treatment of acute renal failure
SI1180121T1 (en) Long lasting insulinotropic peptides
WO2003022208A3 (en) Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
MXPA05000880A (es) Probioticos para funciones neuromusculares del intestino.
MX353044B (es) Liberacion sostenida de anti-infecciosos.
ATE401892T1 (de) Verwendung von pharmazeutischen zubereitungen enthaltend oxcarbazepin im nüchternzustand
WO2002020466B1 (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
HK1087336A1 (en) Pharmaceutical composition comprising lumiracoxib
PL321238A1 (en) Compositions of amino acids and their application in clinical nourishing
EP2767291A3 (en) Treatment of glycogen storage disease type II
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
DE69622855D1 (de) Pharmazeutische zusammensetzungen welche lactobacillus plantarum und arginin beinhalten
PL1643999T3 (pl) Pirydoksamina do zastosowania w leczeniu nefropatii cukrzycowej w cukrzycy typu II
IL161670A0 (en) Thymosin alpha 1 peptide/polymer conjugates
CA2373252A1 (en) Long lasting anti-angiogenic peptides
NZ514911A (en) Use of N-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
HK1075654A1 (en) Hyperforin derivatives, the use thereof and formulations containing them
CA2238920A1 (en) Nephroprotective pharmaceutical composition and use thereof
SI0711163T1 (en) Use of benzydamine in the treatment of pathological conditions caused by tnf
WO2001039725A3 (en) Drug preparations
MD1469G2 (ro) Metodă de tratament al şocului combustional
徐蕴华 et al. The use of traditional Chinese herb medicine in the treatment of maternal-fetal blood group incompatibility: attached a case report
RO117893B1 (ro) Metodă de anestezie generală, la cabaline